@Article{096504015X14452563485986,
AUTHOR = {Caroline Jamison, Debra Nelson, Mete Eren, Dron Gauchan, Ryan Ramaekers, Max Norvell, Mehmet Sitki Copur},
TITLE = {What Is the Optimal Dose and Schedule for Dasatinib in Chronic Myeloid  Leukemia: Two Case Reports and Review of the Literature},
JOURNAL = {Oncology Research},
VOLUME = {23},
YEAR = {2015},
NUMBER = {1-2},
PAGES = {1--5},
URL = {http://www.techscience.com/or/v23n1-2/57563},
ISSN = {1555-3906},
ABSTRACT = {Efficacy and safety of dasatinib in chronic phase (CP) chronic myelogenous leukemia (CML) patients has 
been well established. Initially approved dose and schedule of 70 mg twice daily has been changed to 100 mg 
once daily after demonstration of the same efficacy with less toxicity. Some patients require significant dose 
reductions to enable continued treatment with dasatinib. Even at a dose of 80 mg once daily, several patients 
may require further dose reductions due to substantial toxicity while maintaining good control of their disease. 
We report two CP-CML patients achieving and maintaining major molecular responses while on very low 
doses of dasatinib, ultimately achieving undetectable levels of BCR-ABL fusion transcript in their peripheral 
blood. Observations of several CP-CML cases responding remarkably well to dasatinib despite very low dose 
and frequent dose interruptions challenge our current understanding and the accuracy of the data regarding the 
optimum dose and schedule of this drug. In selected intolerant patients, low-dose dasatinib therapy may be a 
safe and effective alternative treatment option before a treatment discontinuation or change considered.},
DOI = {10.3727/096504015X14452563485986}
}